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In the conducting airways of the lungs, the mobile mucus gel layer sits on top of 
the airway epithelium, and through ciliary beating it is propelled up the trachea into the 
pharynx where it is swallowed and cleared. This gel layer is composed of secreted 
mucins that become hydrated once reaching the airway lumen. Mucins are secreted at 
a baseline rate and at a stimulated rate, dependent on the amount of agonist. Baseline 
secretion is responsible for steady clearance of inhaled particles and pathogens. 
Stimulated secretion is thought to play a role in trapping helminths though mucus 
occlusion in small airways.  
Mucin exocytosis is mediated by a four helix bundle called the SNARE complex. 
Prior to complex formation, three of the four helices are located on the target 
membrane (t-SNARE) and one helix is vesicle bound (v-SNARE). Formation of the 
complex drives fusion of the exocytic vesicle with the plasma membrane. These 
SNARE interactions take place on a scaffold provided by a Munc18 protein. Prior work 
in the Dickey-Tuvim laboratory has shown that different Munc18 proteins mediate 
baseline and stimulated mucin secretion, indicating that different plasma membrane 
exocytic machines underlie baseline and stimulated mucin secretion. 
My project is to answer several questions pertaining to mucin granule biogenesis 
and exocytosis, which have implications in treating diseases related to disordered 
mucin production and secretion. 1) Are the polymeric mucins MUC5AC and MUC5B 
packaged in the same or separate granules? 2) What components of the exocytic 
machinery on mucin granules interact with the plasma membrane machines, and can 
these be used as markers to define mucin trafficking prior to secretion?  
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3) What is the nature of a mucin granule? Does it contain only newly synthesized 
proteins, or does it intersect the endolysosomal system as occurs in lung alveolar 
epithelial secretory cells? 4) Does the mucin granule exocytic machinery become 
associated with granules in the trans-Golgi network? Does the structure of Golgi bodies 




Table of contents 
Acknowledgements ........................................................................................................ iii 
Abstract .......................................................................................................................... iv 
Table of contents ........................................................................................................... vi 
List of figures ................................................................................................................. ix 
List of tables .................................................................................................................... x 
Introduction ...................................................................................................................1 
1. Airway mucus biology .................................................................................................1 
 1.1 Secretory cells .....................................................................................................1 
 1.2 Ciliated cells  .......................................................................................................2 
 1.3 Mucus composition ..............................................................................................3 
2. Mucin structural organization ......................................................................................4 
 2.1 Mucin glycoproteins .............................................................................................4 
 2.2 Structures of MUC5AC and MUC5B ....................................................................4 
 2.3 Mucin glycosylation .............................................................................................7 
3. Mucin production and function ....................................................................................7 
 3.1 Muc5ac ................................................................................................................7 
 3.2 Muc5b ..................................................................................................................8 
vii 
 
4. Mucin secretion ...........................................................................................................8 
 4.1 Constitutive and regulated secretion ...................................................................9 
 4.2 Baseline secretion ...............................................................................................9 
 4.3 Stimulated secretion .......................................................................................... 10 
 4.4 Exocytosis ......................................................................................................... 10 
5. Mucin exocytic machinery ......................................................................................... 12 
 5.1 SNAREs ............................................................................................................ 12 
 5.2 SM proteins ....................................................................................................... 16 
 5.3 Regulatory proteins ........................................................................................... 17 
Mucin in lung disease ................................................................................................. 17 
6. Allergic Asthma ......................................................................................................... 17 
 6.1 Cell biology of allergic asthma ........................................................................... 17 
 6.2 The role of mucus in asthma ............................................................................. 18 
 6.3 Therapeutics ...................................................................................................... 18 
7. Cystic fibrosis ............................................................................................................ 19 
 7.1 Cell biology of cystic fibrosis .............................................................................. 19 
 7.2 The role of mucus in CF .................................................................................... 20 
 7.3 Therapeutics ...................................................................................................... 20 
viii 
 
8. Chronic obstructive pulmonary fibrosis ..................................................................... 21 
9. Idiopathic pulmonary fibrosis .................................................................................... 22 
Results ......................................................................................................................... 24 
10. Muc5ac and Muc5b are stored in the same and separate granules........................ 25 
 10.1 Colocalization of Muc5ac and Muc5b in mouse airways ................................. 25 
 10.2 Colocalization of Muc5ac and Muc5b in human airways ................................. 28 
11. VAMP3 and VAMP8 together mediate mucin granule exocytosis ........................... 30 
 11.1 Both VAMP3 and VAMP8 participate in baseline mucin secretion .................. 30 
 11.2 VAMP8 KO mouse airways spontaneously accumulate relatively more Muc5ac 
than Muc5b ................................................................................................................... 33 
 11.3 VAMP3 and VAMP8 both partially colocalize with Muc5ac and Muc5b in 
metaplastic airway epithelial cells ................................................................................. 34 
12. Mucin granules are purely in a biosynthetic pathway and do not intersect the 
endolysosomal system .................................................................................................. 41 
13. Golgi stacks are dispersed in airway secretory cells ............................................... 45 
Discussion ................................................................................................................... 51 
Methods ....................................................................................................................... 55 
References .................................................................................................................. 63 
Vita ............................................................................................................................... 75 
ix 
 
List of figures 
Figure 1. Airway epithelium .............................................................................................2 
Figure 2. Muc5ac and Muc5b monomers ........................................................................6 
Figure 3. Mucin secretion in proximal and distal airways. ...............................................9 
Figure 4. A generic model of mucin exocytosis ............................................................. 15 
Figure 5. Colocalization of Muc5ac and Muc5b in mouse airways ................................ 27 
Figure 6. Colocalization of MUC5AC and MUC5B in human airways ........................... 29 
Figure 7. Baseline secretion is mediated by both VAMP3 and VAMP8, but VAMP3 does 
not mediate stimulated secretion .................................................................................. 32 
Figure 8. VAMP8 KO mice accumulates more Muc5ac spontaneously in the airway ... 34 
Figure 9. VAMP3 and VAMP8 antibody staining ........................................................... 36 
Figure 10. VAMP3 partially colocalizes with Muc5ac and Muc5b ................................. 38 
Figure 11. VAMP8 partially colocalizes with Muc5ac and Muc5b ................................. 40 
Figure 12. LAMP1 is not present on mucin granules .................................................... 43 
Figure 13. LAMP2 is not present on mucin granules .................................................... 44 
Figure 14. TGN46 dispersed in secretory cells ............................................................. 46 
Figure 15. GRASP55 dispersed in secretory cells ........................................................ 48 
Figure 16. GRASP65 and GRASP55 are dispersed in secretory cells.......................... 49  
x 
 
List of tables 
Table 1. Primary antibodies for airway epithelial cells and mucins ............................... 60 
Table 2. Primary antibodies for Golgi and lysosomes ................................................... 60 




1. Airway mucus biology 
 Overview 
In the lungs, mucus covers the epithelial surface of conducting airways, 
providing a physical barrier against inhaled particles and pathogens. Mucins are 
exceedingly large glycoproteins that form a mesh-like network within the mucus gel 
layer, giving mucus its viscoelastic properties as well as its capability of trapping 
inhaled particles and pathogens. Despite its protective qualities, the inability to clear 
airway mucus by ciliary beating or cough is pathogenic in diseases such as asthma and 
cystic fibrosis (1). In addition, the synthesis and trafficking of mucins plays a pathogenic 
role in fibrotic interstitial lung diseases. Further understanding of mucin secretion is 
therefore necessary to improve treatment of lung diseases. 
 1.1 Secretory cells 
The airway is lined by a pseudostratified epithelium composed primarily of 
superficial secretory cells and ciliated cells, with underlying basal cells in proximal 
airways, and small numbers of scattered neuroendocrine cells, ionocytes, and tuft cells 
(Fig. 1A). Secretory cells are further subcategorized based on microscopic appearance 
as either club or goblet cells depending on the number of intracellular mucin granules. 
A variety of products are secreted from secretory cells including the mucins MUC5AC 
and MUC5B and immunomodulatory molecules such as secretoglobins (2). In large 
airways, submucosal glands also contribute to the mucus gel layer. Within submucosal 
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glands, serous cells secrete fluid and antimicrobial peptides such as defensins and 
lysozyme while mucous cells secrete mucins (1).  
 1.2 Ciliated cells  
Ciliated cells are the main contributors to clearance of the mucus gel layer. Each 
ciliated cell has 200-300 cilia that range in length from 7 µm in proximal airways to 4 
µm in distal airways (3). Ciliary beating propels the mucus from distal airways to 
proximal airways and through the vocal cords where it is eventually swallowed and 
cleared by the gastrointestinal tract. While ciliated cells do not secrete mucins, they do 
have transmembrane mucins, glycosaminoglycans, and other glycoconjugates that 
attract water with a higher osmotic pressure than mucus, resulting in the formation of a 




Figure 1. Airway epithelium. (A) Ciliated and secretory cells line the conducting 
airways. Each ciliated cell has 200-300 cilia that range in length from 7 µm in the 
proximal airway to 4 µm in the distal airway. Secretory cells contain large yellow 
mucin granules that can reach up to 1 µm in diameter and small black granules 
which contain proteins. (B) Electron micrograph of a Muc5b polymer partially 
expanded after secretion. The white arrow indicates a globular node where 
monomers appear to be connected. A polymer can have up to 20 monomers 
connected in an end-to-end fashion. (C) Electron micrograph of an extended Muc5b 
polymer showing a monomer approximately 500 nm in length. Reproduced with 
permission from The New England Journal of Medicine, Copyright Massachusetts 
Medical Society. Fahy, J. V., and B. F. Dickey. 2010. Airway mucus function and 
dysfunction. N Engl J Med 363: 2233-2247. 
 
 1.3 Mucus composition 
 Normal airway mucus is composed of approximately 98% water and 2% solids. 
Of the solids, mucins account for one-third with salts and non-mucin proteins the 
remainder. Mucins are 50-90% carbohydrate and can absorb several hundred times 
their weight in water (1). The degree of hydration significantly affects the viscoelastic 
and adhesive-lubricant properties of mucus, resulting in dramatic differences in the 
ease with which it is cleared by ciliated cells. 
 The mucus gel layer sits on top of the denser periciliary layer, which normally 
prevents secreted mucins from touching the epithelial cell surface in the gel-on-brush 
model (4). Within the periciliary layer, airway epithelial cells release adenosine 
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triphosphate (ATP) in response to mechanical stress. Extracellular ATP reaches a 
concentration that is sufficient activate P2Y2 purinergic receptors on secretory cells, 
tonically inducing secretion at a low baseline rate. When the rate of ATP release is 
increased due to inflammatory or mechanical stimuli, or other inflammatory mediators 
such as histamine are released, intense phasic (stimulated) mucin secretion occurs (5, 
6). 
2. Mucin structural organization 
 2.1 Mucin glycoproteins 
There are seven mucins expressed in the lungs, of which four are 
transmembrane mucins and three are secreted. Muc1 is found on the apical surface of 
airway epithelial cells, localizing predominantly on microvilli. Muc4 and Muc20 are 
found on ciliated cells, localizing to cilia (7). Muc16 is the largest mucin produced in the 
airway containing both a transmembrane domain and a proteolytic cleavage site where 
it can be cut to become part of the mobile gel layer (8).  
Muc5ac, Muc5b, and Muc7 are secreted, but Muc7 does not polymerize to form 
a gel. Muc5ac and Muc5b are the predominant gel-forming mucins in the airway (9). 
Muc5ac is produced in proximal human airways and far less in distal airways under 
non-metaplastic conditions. Muc5b is expressed throughout the conducting airway and 
in submucosal glands (10). Mouse airways are akin to human distal airways of 
comparable diameter, with Muc5b being the predominant secreted mucin in non-
metaplastic conditions. 
 2.2 Structures of MUC5AC and MUC5B 
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Mucins are large macromolecules with the apoprotein ranging from 3000-5000 
amino acids in sequence. Muc5ac and Muc5b monomers are approximately 500 nm in 
length, and can form homotypic polymers comprised of up to twenty monomers (Fig. 
1B-C) (1). Mucin monomers homodimerize C-terminal-to-C-terminal in the endoplasmic 
reticulum (ER) and the homodimers polymerize N-terminal-to-N-terminal with further C-
terminal polymerization in the Golgi body. 
Muc5ac and Muc5b monomers contain von Willebrand factor D (vWD)-like 
domains terminally with cysteine-rich domains (CysD) and proline, threonine, serine 
(PTS) rich sequence centrally (Fig 2A). Polymerization occurs at the vWD-like terminal 
domains, which have cysteine-rich regions that allow disulfide bonds to form. PTS 
tandem repeats are sites of O-glycosylation and are present in all mucins. The number 
of repeats and specific sequences are variable between mucin types, thus affecting 
glycosylation patterns and physical properties. CysD domains are interspersed among 
PTS domains and are thought to confer flexibility and provide additional sites for 
mannosylation. Mannosylation has a role in intracellular trafficking, protein folding, and 
localization, and is thought to be essential for Muc5ac and Muc5b maturation from the 




Figure 2. Muc5ac and Muc5b monomers. (A) Muc5ac and Muc5b monomers 
contain von Willibrand factor D (vWD)-like domains terminally with cysteine-rich 
domains (CysD) and proline, threonine, serine (PTS) rich sequence centrally. (B) 
Four core glycosylation types. β1-3 linkage of galactose to N-acetylgalactosamine 
(GalNAc) to form core 1. Additional β1-6 linkage of N-acetylglucosamine (GlcNAc) to 
core 1 to form core 2. β1-3 linkage of GlcNAc to GalNAc to form core 3. Additional 
β1-6 linkage of GlcNAc to core 3 to form core 4. Elongation with different sugars to 
form glycans that can branch further depending on the core type. Reprinted with 
permission from the Biochemical Society Transactions. Symmes, B. A., A. L. 
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Stefanski, C. M. Magin, and C. M. Evans. 2018. Role of mucins in lung homeostasis: 
regulated expression and biosynthesis in health and disease. Biochem Soc Trans 46: 
707-719. 
 
 2.3 Mucin glycosylation 
During the initiation phase of O-glycosylation in the Golgi, N-
acetylgalactosamine (GalNAc)-transferase adds a GalNAc to the hydroxyl side of a 
serine or threonine in PTS domains. Afterward, neutral sugars, galactose (Gal) or 
GalNAc are added to create four different core types that are elongated with different 
sugars to form glycans that can branch further depending on the core type (Fig 2B). 
Glycosylated structures can terminate in Gal or GalNAc (uncapped) or with sialic acid 
or sulfate (capped). Glycans can also be further modified with the addition of fucose. 
The extent of glycosylation that a mucin monomer undergoes is enough to increase its 
mass 3-5 fold (9). 
3. Mucin production and function 
 3.1 Muc5ac 
Very little Muc5ac is present in mouse airways and human distal airways under 
non-metaplastic conditions (10-12). However, during allergic inflammation Muc5ac 
production can increase 40-fold while Muc5b only increases 3-10 fold (1). This drastic 
increase in Muc5ac during inflammation has made it a detrimental factor in muco-
obstructive diseases such as asthma, cystic fibrosis (CF), and chronic obstructive 
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pulmonary disease (COPD). The regulation of Muc5ac is therefore of interest due to its 
pathological implications.  
Epidermal growth factor receptor (EGFR) signaling has been shown to induce 
Muc5ac expression while Foxa2 represses it (13, 14). Besides EGFR signaling, type 2 
inflammatory cytokines such as interleukin (IL)-13 also induce Muc5ac expression 
through binding of hypoxia-inducible factor (HIF)-1 to the promoter region and 
upregulation of SAM pointed domain-containing ETS transcription factor (SPDEF) to 
inhibit Foxa2 mediated repression (9, 15, 16). 
Under normal conditions, Muc5ac knockout (KO) mice have normal mucociliary 
clearance. In an allergic asthma model, Muc5ac KO mice are protected with less 
severe mucus occlusion compared to wild type (WT) mice (12). However, Muc5ac KO 
mice are susceptible to chronic worm infections, and Muc5ac is required for clearance 
of helminths from the cecum (17). Muc5ac also plays a vital role in trapping parasites in 
the lungs (18) 
 3.2 Muc5b 
Muc5b is the predominant gel-forming mucin produced in mice responsible for 
clearance of inhaled particles and microbes. While transcriptional mechanisms are not 
yet well understood, transcription factor NK2 homebox 2-1 (NKX2-1) also known as 
thyroid transcription factor-1 (TTF-1) represses Muc5b gene expression while GATA-6 
activates it (19). 
In Muc5b KO mice, there is an increase in mortality due to the inability to clear 
conducting airways of particles and pathogens. Even with functional cilia, Muc5b KO 
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mice had chronic bacterial infections and accumulation of materials such as hair is 
found in the posterior nasopharynxes and trachea (20). A study of Muc5b heterozygous 
KO mice found that there was approximately 50% reduction in mucociliary clearance 
compared to WT, indicating that Muc5b is limiting for mucociliary clearance (21). 
4. Mucin secretion 
 4.1 Constitutive and regulated secretion 
All cells have a constitutive secretory pathway in which lipids and proteins 
undergo continuous exocytosis from post-vesicles to maintain plasma membrane 
integrity, regardless of external stimuli. Some specialized cells have a regulated 
secretory pathway in which granules are secreted in response to external stimuli. Mucin 
secretion is ligand dependent, making it a regulated process (22).   
 4.2 Baseline secretion 
Mucin production and mucin secretion are two separate processes. In 
uninflamed conditions, the rates of mucin production and secretion closely match, and 
very little mucin accumulation is visible in histochemical stains (Fig. 3, left column). 
With exposure to an allergen such as ovalbumin (OVA), mucin production increases in 





Figure 3. Mucin secretion in proximal and distal airways. Top row shows formalin 
fixed, Alciab blue and periodic acid-Schiff (AB/PAS) staining of mouse proximal 
airway with intracellular mucin stained purple. Bottom row shows methacarn fixed, 
periodic acid fluorescent-Schiff (PAFS) staining of mouse distal airways with mucin 
stained red. Left column shows uninflamed airway with little mucin accumulation. 
Middle column shows mucin hyperproduction (mucous metaplasia) with addition of 
ovalbumin (OVA). Right column shows stimulated secretion with addition of excess 
ATP. Scale bar is 10 µm in the top row and 50 µm in the bottom row. Reprinted with 
permission of the American Thoracic Society. Copyright © 2020 American Thoracic 
Society. All rights reserved. Annals of the American Thoracic Society is an official 
journal of the American Thoracic Society. Jaramillo, A. M., Z. Azzegagh, M. J. Tuvim, 





 4.3 Stimulated secretion 
  The rate of mucin secretion can be stimulated with the addition of excess ATP, 
as seen in the mouse airway (Fig. 3, right column, top row). The rapid release and 
hydration of accumulated intracellular mucin results in mucus occlusion of small 
airways (Fig. 3, right column, bottom row). Degranulation events in goblet cells have 
been studied by high speed videomicroscopy following the addition of ATP. Stimulated 
secretion had a 1,760-fold increased rate over baseline, with similar findings between 
normal and CF human airway (22-24). 
 4.4 Exocytosis 
The central molecular mediators of exocytosis are soluble N-ethylmaleimide-
sensitive factor attachment protein receptors (SNAREs). However, before SNAREs 
drive fusion of a vesicle with the plasma membrane, certain steps need to occur. These 
include tethering, docking, priming, and fusion. It has been established that Rabs 
participate in each of these steps.  
Rab proteins are a part of the Ras-like GTPase super family. Over 60 Rabs are 
expressed in humans, and many studies have localized Rab proteins to distinct 
intracellular compartments with roles in transport between organelles. For each step of 
exocytosis, Rabs interact with proteins that act as effectors to transduce signaling. 
Multiple different Rabs can be on a vesicle and an exchange of Rabs occur at different 
stages of exocytosis. 
Notable Rabs in secretion include Rab8 which participates in trafficking from the 
trans-Golgi network (TGN) to the plasma membrane for the constitutive secretory 
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pathway, and Rab3 which participates in regulated secretion (25). The isoform Rab3d 
has been reported by the Dickey/Tuvim Laboratory to be restricted to airway secretory 
cells expressing club cell secretory protein (CCSP) (11, 26). 
In exocytosis, tethering refers to linking the vesicle with the target membrane, 
bringing the membranes close together in preparation for fusion. There appears to be 
two general class of tethering factors - large coiled-coil proteins, and multi-subunit 
tethering complexes that include four to eight related proteins.  
A large number of coiled-coiled proteins have been found associated to Golgi 
membrane called “golgins”.  Golgi matrix (GM) 130, also known as golgin-95, is found 
to associate with Golgi reassembly-stacking protein (GRASP) 65, which is a found on 
the cis-Golgi. The GM130:GRASP65 complex is a Rab1 effector. Binding to Rab1-GTP 
is required for ER coat protein (COP) II vesicle fusion to the cis-Golgi (27). 
Docking is generally understood as the stage in which vesicles are at a minimal 
distance from the target membrane prior to fusion. Although mechanistically not fully 
understood, Sec1/Munc18 (SM) proteins have been implicated (28). Mouse chromaffin 
cells deficient in Munc18a, also known as Munc18-1, have a docking defect in which 
calcium-dependent large dense core vesicle exocytosis was reduced 10-fold. In 
contrast, bovine chromaffin cells overexpressing Munc18a had an increase in fusion-
competent vesicles (29). 
Priming prepares vesicle for fusion. In the case of SNARE mediated vesicle 
fusion, complexins have been found to bind the SNARE complex, inhibiting fusion. 
Calcium bound synaptotagmin (Syt) interaction then releases this inhibition, thus 
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priming the SNARE complex (30). Finally, fully coiled SNARE proteins provide the 
energy necessary for membrane fusion. 
5. Mucin exocytic machinery 
 5.1 SNAREs 
SNARE proteins are required for all intracellular trafficking of vesicles on the 
endocytic and exocytic pathways. Each SNARE protein has a SNARE motif that is 
approximately 70 residue in length. This SNARE motif is capable of assembly with 
three other SNAREs to form a four helix complex in parallel (30). There are four groups 
of SNAREs - Qa, Qb, Qc, and R-SNARE (31). R-SNAREs have an arginine at the 
midpoint of the conserved zero ionic layer, and Q-SNAREs have glutamine at that 
place. Polar interactions at the center of the hydrophobic SNARE assure correct 
alignment of the SNARE complex.  
SNAREs are also classified as v-SNARE and t-SNARE, with R-SNAREs 
associated to the vesicle (v)-SNAREs and Q-SNAREs to the target membrane (t)-
SNAREs (32). In exocytosis, a t-SNARE synaptosomal-associated protein (SNAP) 
contributes two helices and a Syntaxin contributes one helix to the SNARE complex. 
The vesicle associated membrane protein (VAMP), located on the vesicle, contributes 
the fourth helix to the SNARE complex (Fig. 4) (22). 
VAMPs are unique in that they are the only SNARE located on the vesicle. Many 
studies of vesicle trafficking have been done in neurons with a synaptic vesicle as a 
model. The most abundant protein decorating a synaptic vesicle is VAMP2, with 
approximately 70 copies per vesicle (33). This makes VAMPs an attractive granule 
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marker in the process of understanding mucin secretion. In Calu-3 cells, a lung 
epithelial cell line, VAMP8 is the most abundantly expressed VAMP, with VAMP3 
coming in second (34). Knowing that baseline and stimulated secretion are present, it is 
likely that different VAMPs mediate each exocytic machinery. Potentially, even Muc5ac 
and Muc5b may be segregated with Muc5b secretion favoring the baseline secretory 
machinery and Muc5ac favoring the stimulated secretory machinery, based upon the 
roles of Muc5ac in trapping migrating helminths and Muc5b providing baseline 
mucociliary clearance. 
Specific SNAREs in the airway include SNAP23, which participates in both 
baseline and stimulated mucin secretion as shown by the Dickey/Tuvim Laboratory 
(35). SNAP23 contains two t-SNARE helices connected by a linker region that contains 
palmitoyl groups, allowing it to be anchored to the membrane. In unpublished work, the 
Dickey/Tuvim laboratory has found that Syntaxin-3 participates in stimulated mucin 
secretion, but Syntaxin function in baseline mucin secretion has not yet been studied. 
VAMP8 has been found to mediate stimulated airway mucin secretion, and to be 
localized to MUC5AC-containing granules (34). The details of my investigations of 
VAMP proteins mediating baseline mucin secretion are described later in the thesis 
text. However in brief, I found that both VAMP8 KO and VAMP3 KO mice had a 









Figure 4. A generic model of mucin exocytosis. The left depicts specific proteins 
participating in airway mucin exocytosis. The four helices that make up the SNARE 
complex is represented by black bars, including synaptosomal-associated protein 
(SNAP), syntaxin (Stx), and vesicle associated membrane protein (VAMP). The SM 
protein, mammalian uncoordinated (Munc)-18, is shown interacting with Stx at the 
plasma membrane along with the regulatory protein Munc13. The right shows a 
simplified signaling pathway of mucin exocytosis over a time course. An agonist 
binds a heptahelical receptor at the plasma membrane, activating trimeric G protein 
(Gq) then phospholipase-Cβ (PLC), generating secondary messengers diacylglycerol 
(DAG) and inositol triphosphate (IP3). DAG binds Munc-13, allowing Stx to be in an 
open conformation at the plasma membrane. IP3 induces calcium release from the 
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endoplasmic reticulum (ER). Free calcium activates synaptotagmin (Syt) which 
promotes further coiling of the SNARE complex enabling fusion and release of mucin 
into the extracellular space. Munc18 provides acts as a scaffold, bringing the 
SNAREs together prior assembly. Reprinted with permission of the American 
Thoracic Society. Copyright © 2020 American Thoracic Society. All rights reserved. 
Annals of the American Thoracic Society is an official journal of the American 
Thoracic Society. Jaramillo, A. M., Z. Azzegagh, M. J. Tuvim, and B. F. Dickey. 2018. 
Airway Mucin Secretion. Ann Am Thorac Soc 15: S164-S170. 
 
 5.2 SM proteins 
SM proteins provide a physical platform that is critical for proper SNARE 
assembly. Seven isoforms are present within mammals, and of the seven, Munc18a, 
Munc18b, and Munc18c have been found to play roles in secretion (36). Munc18a, 
Munc18b, and Munc18c KO mice were all nonviable after birth. Thus, Munc18 
conditional deletant mice were generated in the Dickey/Tuvim Laboratory, in which the 
deletion was only in airway epithelial cells. It was discovered that Munc18a deletant 
mice spontaneously accumulated mucin, signifying a baseline secretion defect. With 
addition of excess ATP, Munc18a deletant mice were able to secrete just like WT mice, 
indicating that the stimulated secretory pathway was unaffected by the absence of 
Munc18a. In contrast, Munc18b deletant mice also showed a modest amount of 
spontaneous mucin accumulation, but there was a severe defect in stimulated 
secretion. Munc18c deletant mice had no observed secretory defect (36). These 
findings identified the presence of two separate exocytic machineries acting at the 
17 
 
plasma membrane in airway mucin secretion. These are defined by the role of 
Munc18a in baseline mucin secretion, and Munc18b in stimulated mucin secretion. 
Presumably, Munc18c acts in basolateral secretion, as it does in other polarized cell 
types. 
 5.3 Regulatory proteins 
As mentioned previously, Synaptotagmins (Syt)s plays a crucial role in priming. 
There are seventeen Syt isoforms, but not all are calcium sensitive. Syt2 was found by 
the Dickey/Tuvim laboratory to be the calcium sensor in stimulated mucin secretion 
(26). Besides Syt2, other regulatory proteins involved in priming include Munc13. 
Munc13 is thought to act in concert with Munc18 to opens up Syntaxin (30). Munc13 
has 5 isoforms, and only Munc13-2 and Munc13-4 are found in the airway. Munc13-2 
KO mice had a baseline mucin secretion defect and a partial stimulated secretion 
defect as found by the Dickey/Tuvim laboratory in collaboration with the Davis 
laboratory (37). Mice with that were deficient in both13-2 and 13-4 had a greater 
stimulated secretion defect (unpublished data, Dickey/Tuvim Laboratory). 
Mucus dysfunction in lung disease 
6. Allergic Asthma 
 6.1 Cell biology of allergic asthma 
Over 300 million people worldwide have asthma, making it the most common 
chronic inflammatory lung disease. It is more prevalent in developed countries and 
more common in urban areas. Many factors play a role in the development of asthma 
including age, sex, and environment. Three characteristics of asthma are increased 
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eosinophils in the lungs, airway smooth muscle hyper-responsiveness to contractile 
stimuli, and mucous metaplasia in airway epithelium. There are many subsets of 
asthma but here we will focus on allergic asthma. 
Allergic asthma is a Type 2 inflammatory disease that is sustained by TH2 cells. 
During allergen sensitization, airway epithelial cells through TLR stimulation activate 
the MyD88 pathway which induces the production of IL-25, IL-33, and TSLP. These 
cytokines then activate dendritic cells (DCs), mast cells, basophils, and type 2 innate 
lymphoid cells (ILC2s). ILC2s then produce IL-5, IL-9, and IL-13 as a response. 
DCs sample inhaled particles in the lumen. After activation, DCs migrate to 
lymph nodes to present the antigen to naïve T cells, driving T cell differentiation into 
TH2 cells. TH2 cells then secrete pro-allergic cytokines IL-3, IL-4, IL-5, IL-9, IL13, and 
granulocyte-macrophage colony-stimulating factor (GM-CSF). Of the cytokines 
involved, IL-4, IL-9, IL-13 are sufficient in causing mucous metaplasia (38).  
 6.2 The role of mucus in asthma 
Mucus plugging of the airway is commonly seen in patients with fatal asthma (1). 
As previously mentioned, IL-13 contributes to the sudden upregulation of mucin 
production, particularly Muc5ac. In humans, an increase of Muc5ac and decrease of 
Muc5b is specific to TH2 type asthma (39). The change in mucin ratio affects mucous 
physical properties, which makes clearance more difficult. In the case of asthma, 
mucus obstruction, inflammation, and airway smooth muscle contraction make a deadly 
combination. 
 6.3 Therapeutics 
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Inhaled corticosteroids combined with β-adrenergic agonists are the most 
important current treatments for asthma. β-adrenergic agonists are bronchodilators that 
relax the smooth muscle airway, providing a quick relief from airflow obstruction. 
Inhaled corticosteroids have an anti-inflammatory effect, reducing leukocytes in the 
mucosa and submucosa, goblet cell metaplasia, and angiogenesis (40). Monoclonal 
antibodies directed against IgE, IL-5,or IL-4R-alpha are newer agents directed at 
reducing inflammation in severe chronic asthma (41) 
For mucus-specific treatments, inhaled hypertonic saline is used to hydrate the 
airway. This reduces mucous viscoelasticity and promotes mucociliary clearance (42). 
N-acetylcysteine breaks disulfide bonds in mucin polymers and is effective in 
solubilizing sputum ex vivo, however due to the fact that it is an irritant in the airway 
with very low potency in breaking disulfide bond, it is not routinely used for mucus 
clearance in vivo (1). Newer reducing agents with greater potency and less toxicity are 
in development (43). 
Another potential area of drug therapy may be in targeting exocytic machinery 
components. In an IL-13 induced allergic asthma model, Munc18b deletant mice were 
protected compared to their WT counterparts with a 62% decrease in luminal mucus. 
This is an attractive concept since deletion of Munc18b does not affect baseline 
secretion needed for mucociliary clearance (36). 
7. Cystic fibrosis 
 7.1 Cell biology of CF 
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Cystic fibrosis (CF) is the most common life-limiting genetically inherited disease 
in Caucasians, affecting over 70,000 people worldwide and 1 out of every 2,500-4,000 
newborns in North America and Europe (44). CF is cause by mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene. CFTR is an integral 
transmembrane protein that transports chloride and bicarbonate anions across apical 
epithelial cell surfaces in the lungs, sinuses, gastrointestinal tract, sweat glands, and 
elsewhere. Dysfunction in CFTR results in abnormally viscous mucus, chronic bacterial 
infection, and inflammation, which is particularly devastating in lungs and the primary 
cause of morbidity and mortality.  
There are five classes of CF mutations: Class I where no CFTR protein is 
created; Class II where CFTR is misfolded and does not reach the cell surface; Class 
III where the protein reaches the cell surface but has a gating problem; Class IV where 
CFTR is at the cell surface but the ion channel is faulty; and class V where there is an 
insufficient amount of CFTR created (45). 
Due to the decrease in anion secretion by CFTR, insufficient sodium is present 
in the airway lumen. Salt concentration increases intracellularly, drawing in water, and 
dehydrating the periciliary and mucus gel layers. This causes mucus adhesion to the 
airway epithelial cell surface, affecting mucociliary clearance (46). 
The sputum from CF patients was found to contain IL-1β, IL-1α, TNF-α , IL-
17A/F, neutrophil elastase, and the neutrophil chemoattractant, IL-8. The cytokine IL-
1β increases both Muc5ac and Muc5b production, with Muc5b being more prominent. 
CF is also characterized by neutrophilic inflammation in the absence of infection, 
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thought to be due to epithelial hypoxia and apoptosis due to adherent mucus plaques 
(47).  
 7.2 The role of mucus in CF 
In healthy lungs, mucus aids in clearance of inhaled pathogens in the airway. In 
CF lungs, mucus becomes concentrated due to mucin overproduction and dehydration 
from salt imbalances. This leads to a mucociliary clearance defect, chronic bacterial 
infection, and mucus plug formation (48). 
 7.3 Therapeutics 
CF drugs are divided into potentiators and correctors. Ivacaftor is a potentiator 
targeting class III mutations by improving ion movement through the channels. During 
Phase III clinical trials, 75% of the subjects taking ivacaftor for 24 weeks had a 5% or 
more increase in forced expiratory volume in 1 second (FEV1), a readout for lung 
function (44). Tezacaftor was developed as a corrector for the CFTR protein, targeting 
class II mutations. Combination therapy of ivacaftor and tezacaftor has been approved 
in 2018 (45). 
For the treatment of pathogenic mucus, inhaled hypertonic saline was shown to 
improve mucus clearance and lung function in CF patients. Mucus clearance rate was 
sustained for more than 8 hours, suggesting that hydration of the airway led to 
improved mucus clearance (49). 
Targeting mucin secretion may have therapeutic benefits for CF. In a mouse 
model mimicking CF, Munc18b deletion decreased mucous occlusion by 66% as 
demonstrated by the Kreda laboratory in collaboration with the Dickey/Tuvim 
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laboratory. Neutrophilic inflammation was still present in mice, therefore potential drugs 
targeting exocytic proteins may work best in combination with other CF drugs (36).  
8. Chronic obstructive pulmonary fibrosis 
Chronic obstructive pulmonary disease (COPD) is characterized as persistent 
airflow limitation due to either genetic or environmental factors or both. Approximately 
2.7 million deaths worldwide are attributed to COPD each year (50). This section 
focuses primarily on COPD associated with long-term cigarette smoking. Cigarette 
smoking is a major environmental factor in developing COPD and is associated with 
increased mucin concentration  (51). Although not all smokers develop COPD, the long 
term repeated process of inhaling particulates from cigarettes is sufficient for inducing 
lung injury. Toxic gases also enter the lungs, inducing oxidative stress and 
inflammatory responses. Among these gases, acrolein in particular has been shown to 
induce mucous metaplasia (52). The infiltration of neutrophils, macrophages, and 
lymphocytes is associated with disease severity. Features of COPD include fibrotic 
thickening of airway walls, damage in the alveolar region termed emphysema, and 
mucus hyper secretion (53). Compared to people who have never smoked, current or 
former smokers with COPD have 3 times as high Muc5b and 10 times as high Muc5ac, 
with Muc5b being the predominant mucin found in sputum (54).  
9. Idiopathic pulmonary fibrosis 
  Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease in 
which scarring of the alveolar region occurs. IPF affects approximately 3 million people 
worldwide, with incidence increasing with age. Repetitive lung injury could lead to a 
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maladaptive response in genetically susceptible individuals. Risk factors associated 
with IPF include smoking, chronic viral infections, and genetics. Although fibrosis 
primarily occurs in the alveolar region, a risk factor in developing IPF is the gain-of-
function mutation of MUC5B (55).  
In humans, a polymorphism that causes overexpression of MUC5B was found to 
be a risk factor for IPF (56). Surprisingly, even though 20% of Caucasians have the 
polymorphism, IPF remains a rare disease. This could be speculated that the mutation 
is selected for despite the associated risk of developing interstitial lung disease, likely 
to due proteostasis stress. A reason for the selection could be due to enhanced 
protection of the airway epithelium from inhaled pathogens. This may be comparable to 
how people with the allele for sickle hemoglobin are protected against malaria (57). 
MUC5B is found in distal airways and in honeycomb cysts that form in human IPF 
lungs. In mice, overexpression of Muc5b is associated with fibrogenesis following lung 
injury. However, with treatment of a mucolytic agent there is a decrease of collagen 







As described in the Introduction section, secretion of the polymeric gel-forming 
mucins MUC5AC and MUC5B into the airway lumen is an essential defense against 
particles and pathogens. However, under some circumstances this process causes 
pathophysiology. Prior work in our laboratory found that there are two distinct molecular 
exocytic machines at the plasma membrane that mediate baseline and stimulated 
mucin secretion. My work addresses several questions that arise from this prior work:  
1) Are the polymeric mucins MUC5AC and MUC5B packaged in the same or 
separate granules. If separate, are they secreted exclusively by only one of 
the exocytic machines? 
2) What components of the exocytic machinery on mucin granules interact with 
the plasma membrane machines, and can these be used as markers to 
define mucin trafficking prior to secretion? 
3) What is the nature of a mucin granule? Does it contain only newly 
synthesized proteins, or does it intersect the endolysosomal system as 
occurs in lung alveolar epithelial secretory cells? 
4) Does the mucin granule exocytic machinery become associated with 
granules in the trans-Golgi network? Does the structure of Golgi bodies in 
airway secretory cells change with mucous metaplasia? 
Answering these questions is vital to understanding mucin granule biogenesis 
and exocytosis, which has implications for understanding and treating diseases of 
disordered mucin production and secretion. 
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10. Muc5ac and Muc5b are stored in the same and separate granules 
 10.1 Colocalization of Muc5ac and Muc5b in mouse airways 
To address mucin packaging within granules, we examined mice stimulated with 
either IL-13 or IL-1β to upregulate Muc5ac production (mucous metaplasia) since very 
little Muc5ac is produced under non-inflammatory conditions. The cytokine IL-13 is a 
cytokine implicated in asthma and IL-1β is implicated in CF and COPD. We used both 
cytokines to generalize our findings and different doses were administered to determine 
optimal levels sufficient for Muc5ac expression and visualization but not excessive 
expression to allow adequate resolution of granules. 
Colocalization analysis is generally done to determine the physical association 
of different proteins. Two commonly used methods to determine colocalization are 
measurement of Pearson’s correlation coefficient (PCC) and Mander’s colocalization 
coefficients (MCC). PCC examines the relationship between two proteins on a scale of 
-1 to +1, representing negative correlation and positive correlation in which zero is no 
correlation. MCC has two values, M1 and M2, which quantify the degree of co-
occurrence of two proteins. MCC values are based on a scale of 0 to +1, representing 
non-overlapping and complete overlapping of pixels, respectively (59). 
In IL-13 induced metaplasia, we observed airway secretory cells that expressed 
both Muc5ac (red) and Muc5b (green). A line-scan analysis was performed across the 
longest length of the cell (Fig 5.A), and the plot generated shows areas of no 
colocalization (white triangles) and colocalization (black triangle) of Muc5ac and Muc5b 
(Fig. 5.B). Only cells that produced both mucins were selected for colocalization 
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analysis and generation of PCC and MCC values. The PCC values of 40 cells were 
plotted with a median value of 0.65, signifying a moderate positive correlation of 
Muc5ac and Muc5b in IL-13-treated mouse airways (Fig. 5C). The same cells were 
used to generate MCC values, and the median value for M1 was 0.57 and for M2 was 
0.70 (Fig. 5D). M1 indicates the fraction of green pixels (Muc5b+) that overlap red 
pixels (Muc5ac+), and M2 indicates the fraction of red (Muc5ac+) pixels that overlap 
green pixels (Muc5b+). This analysis showed that a higher fraction of Muc5ac is 
colocalized with Muc5b and that more Muc5b granules do not contain Muc5ac. Some 
granules containing only Muc5b can be seen at the apical surface of the secretory cell 






Figure 5. Colocalization of Muc5ac and Muc5b in mouse airways. (A) 
Representative image of a mouse airway treated with IL-13 and stained with Muc5ac 
(red) and Muc5b (green). (B) Line-scan analysis corresponding to arrow drawn in (A) 
showing no colocalization (white triangle) and colocalization (black triangle). (C) 
Pearson’s correlation coefficient for Muc5ac and Muc5b in airways treated with IL-13. 
Box shows median and interquartile range and whiskers show 10th and 90th 
percentiles. N = 40 cells from 4 mice. PCC = 0.65. (D) Mander’s colocalization 
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coefficients for mouse airways treated with IL-13. M1 indicates the fraction of green 
pixels (Muc5b+) that overlap red pixels (Muc5ac+), and M2 indicates the fraction of 
red (Muc5ac+) pixels that overlap green pixels (Muc5b+). N = 40 cells from 4 mice. 
M1 = 0.57 and M2 = 0.70. (E) Representative image of a mouse airway treated with 
IL-1β and stained with Muc5ac (red) and Muc5b (green). (F) Line-scan analysis 
corresponding to arrow drawn in (E). (G) Pearson’s correlation coefficient for Muc5ac 
and Muc5b in airways treated with IL-1β. N = 17 cells from 4 mice. PCC = 0.75. (H) 
Mander’s colocalization coefficients for mouse airways treated with IL-1β. M1 = 0.68 
and M2 = 0.74. Scale bar is 5 µm.  
 
The same analysis was conducted using IL-1β to induce mucous metaplasia 
(Fig. 5E-H). PCC values of 17 cells were plotted with a median value of 0.75, signifying 
a positive correlation between Muc5ac and Muc5b in IL-1β treated mouse airways (Fig. 
5G). The same cells were used to generate MCC values, and the median value for M1 
was 0.68 and M2 was 0.74 (Fig. 5H). Mucins produced under IL-1β treatment are more 
colocalized than mucins produced under IL-13 treatment.  
 10.2 Colocalization of MUC5AC and MUC5B in human airways 
Colocalization analysis of MUC5AC and MUC5B was also done on human 
proximal airways and distal human airways. In human airways, mucin production is also 
varied, as in mice. Analysis of a proximal human airway revealed a MUC5B-only cell 
adjacent to a MUC5AC and MUC5B containing cell (Fig. 6A). The median PCC value 
for human proximal airways was 0.57 (Fig. 6C), and the median value for M1 is 0.63 
and M2 is 0.66. 
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In distal human airway cells (Fig. 6E-H), the median PCC value was 0.64 while 
M1 was 0.48 and M2 was 0.76. A higher proportion of MUC5AC in distal human airway 
is colocalized with MUC5B than MUC5B colocalized with MUC5AC. 
 
Figure 6. Colocalization of MUC5AC and MUC5B in human airways. (A) 
Representative image of a proximal human airway stained with Muc5ac (red) and 
Muc5b (green). (B) Line-scan analysis corresponding to arrow drawn in (A) showing 
no colocalization (white triangle) and colocalization (black triangle). (C) Pearson’s 
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correlation coefficient for Muc5ac and Muc5b in proximal human airway. Box shows 
median and interquartile range and whiskers show 10th and 90th percentiles. N = 9 
cells. PCC = 0.57. (D) Mander’s colocalization coefficients for proximal human 
airway. M1 indicates the fraction of green pixels (Muc5b+) that overlap red pixels 
(Muc5ac+), and M2 indicates the fraction of red (Muc5ac+) pixels that overlap green 
pixels (Muc5b+). N = 9 cells from 1 subject. M1 = 0.63 and M2 = 0.66. (E) 
Representative image of a distal human airway stained with Muc5ac (red) and Muc5b 
(green). (F) Line-scan analysis corresponding to arrow drawn in (E). (G) Pearson’s 
correlation coefficient for Muc5ac and Muc5b in distal human airway. N = 11 cells 
from 1 subject. PCC = 0.64. (H) Mander’s colocalization coefficients for distal human 
airway. M1 = 0.48 and M2 = 0.76. Scale bar is 5 µm. 
 
11. VAMP3 and VAMP8 together mediate mucin granule exocytosis 
 11.1 Both VAMP3 and VAMP8 participate in baseline mucin secretion 
As described in the Introduction, the v-SNARE present on trafficking vesicles is 
usually a member of the VAMP family. A previous study reported that VAMP8 regulates 
mucin secretion in airway goblet cells (34). With deletion of VAMP8, there was a severe 
defect in stimulated secretion, but the degree of a possible defect in baseline secretion 
was not measured. We decided to pursue the possibility that there is another VAMP 
isoform that mediates baseline secretion only, possibly mirroring how Munc18a 
selectively mediates baseline secretion (36). In the human epithelial lung cell line, Calu-
3, it was found that VAMP8 RNA transcripts were the most abundant, followed by 
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VAMP3 (34). For this reason and because VAMP3 has been found to participate in 
secretion in other cell types (60, 61), we began by examining VAMP3 function. 
 To see if VAMP3 mediates baseline secretion, naïve (uninflamed, non-
metaplastic) WT and VAMP3 KO murine lung sections were stained with PAFS and the 
intracellular mucin content was quantified. PAFS stains glycoconjugates red, therefore 
heavily glycosylated mucins stain intensely (although this does not distinguish between 
mucin types). Typical PAFS image of naïve airways show almost no intracellular mucin 
because the rate of mucin secretion matches the rate of constitutive production, as 
seen in Fig.7A (top row). However, VAMP3 KO mice show an approximately four-fold 
increase in intracellular mucin. This spontaneous accumulation of mucins is indicative 
of a baseline secretion defect. 
To see if VAMP3 also plays a role in stimulated secretion, mucous metaplasia 
was induced in WT and VAMP3 KO mice using an OVA sensitization and challenge 
model. The increase in intracellular mucin accumulation between WT and VAMP3 KO 
mice was comparable rather than measurably increased in KO mice (Fig. 7A, middle 
row), probably because the effect of increased mucin production greatly exceeds the 
effect of impaired baseline secretion. When secretion was stimulated with ATP, the 
amount of intracellular mucin remaining was similar between WT and KO (Fig. 7A, 
bottom row), with fractional mucin release not significantly different between genotypes 
(1.90 for WT and 1.90 for KO, P = 0.5077). These findings indicate that VAMP3 KO 
mice have no measurable defect in stimulated secretion. 
 To determine whether VAMP8 is exclusively involved in stimulated secretion, 
mirroring the exclusive involvement of VAMP3 in baseline secretion, we examined 
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VAMP8 KO mice under naïve conditions. These showed spontaneous accumulation of 
mucin (Fig. 7B) to a degree (seven-fold) greater than that in VAMP3 KO mice. This 
indicates that both VAMP3 and VAMP8 participate in baseline mucin secretion, with 





Figure 7. Baseline secretion is mediated by both VAMP3 and VAMP8, but 
VAMP3 does not mediate stimulated secretion. Representative images of WT and 
KO mouse airway under naïve, metaplastic, and stimulated conditions stained with 
PAFS. Intracellular mucin is red. (A)The top row shows naïve airway of WT and 
VAMP3 KO mouse airway. Under naïve conditions, VAMP3 WT has a median of 0.35 
and VAMP3 KO has a median of 2.20, P = 0.0003, Mann-Whitney test for non-
normal distribution. The second row shows mucous metaplasia induced by OVA. 
Under metaplastic conditions, VAMP3 WT has a median of 6.52 and VAMP3 KO has 
a median of 6.84, P = 0.4155, Student’s 2-tailed t-test for normal distribution. The 
third row shows stimulated secretion of metaplastic airways. VAMP3 WT has a 
median of 1.90 and VAMP3 KO has a median of 1.90, P = 0.5077, Student’s 2-tailed 
t-test. (B)The naïve airway of WT and VAMP8 KO mouse airway. Under naïve 
conditions, VAMP8 WT has a median of 0.47 and VAMP3 KO has a median of 3.28, 
P = 0.0002, Student’s 2-tailed t-test. Box shows median and interquartile range and 
whiskers show 10th and 90th percentiles. Where significant difference is P < 0.05, 
indicated by *. N = 4-5 mice per group. Scale bar is 20 µm. 
 
 11.2 VAMP8 KO mouse airways spontaneously accumulate relatively more 
Muc5ac than Muc5b 
To identify the mucin type spontaneously accumulated, immunofluorescence 
staining of Muc5ac and Muc5b was done on naïve WT, VAMP3 KO, and VAMP8 KO 
mice. VAMP3 KO and VAMP8 KO mice accumulate both Muc5ac and Muc5b (Fig. 8). 
Fluorescence intensity per cell was measured in the airway epithelium of WT, VAMP3 
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KO, and VAMP8 KO mice with two mice per group. Compared to WT, VAMP3 KO mice 
accumulated approximately two-fold more intracellular Muc5b and two-fold more 
Muc5ac. VAMP8 KO mice accumulated three-fold more Muc5b and almost five-fold 
more Muc5ac. 
 
Figure 8. VAMP8 KO mice accumulates more Muc5ac spontaneously in the 
airway. Representative images of WT, VAMP3 KO and VAMP8 KO mouse airways 
stained with antibodies against Muc5ac and Muc5b. Scale bar is 20 µm. 
 
 11.3 VAMP3 and VAMP8 both partially colocalize with Muc5ac and Muc5b in 
metaplastic airway epithelial cells 
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VAMPs are located on the surface of trafficking vesicles in other cell systems 
(33), and the functional effects of deletion of VAMP3 and VAMP8 on mucin secretion 
suggest these proteins will be found on the surface of mucin granules. As noted in the 
Introduction, VAMP2 is the most abundant granule membrane protein in neurons (33). 
To visualize whether or not VAMP3 and VAMP8 colocalize with either Muc5ac or 
Muc5b or both, we generated highly specific antibodies for each VAMP (Fig. 9). No 
granule structures were detected in VAMP3 KO tissue (Fig. 9A) or VAMP8 KO tissue 
by the cognate antibodies (Fig. 9B). However, there was some non-specific binding to 
the basal bodies of ciliated cells which was identified with an anti-acetylated tubulin 
antibody. Granular structures were detected in secretory cells of WT mice with both 




Figure 9. VAMP3 and VAMP8 antibody staining. (A) WT and VAMP3 KO mouse 
airways stained with antibodies against VAMP3, acetylated tubulin (AcTub), and 
DAPI. (B) WT and VAMP8 KO mouse airways stained with antibodies against 




 In mouse airways treated with IL-13 to induce Muc5ac expression, VAMP3 
appears to partially colocalize with Muc5ac and Muc5b (Fig. 10). Some granules 
appear to contain only Muc5b (Fig 10B, green arrowhead) and other granules contain 
both mucins and VAMP3 (Fig. 10B, white arrow). Colocalization patterns in airway 
secretory cells appear to be highly variable (Fig. 10C), in which certain regions and 






Figure 10. VAMP3 partially colocalizes with Muc5ac and Muc5b. (A) 
Representative image of a mouse airway treated with a high dose of IL-13 and 
stained with antibodies against Muc5ac (red) and Muc5b (green) and VAMP3 (blue). 
Dashed box indicates region of interest. (B) Single channel view of Muc5ac, Muc5b, 
and VAMP3 of secretory cells. Final panel shows all three channels merged. The 
green arrowhead indicates lack of colocalization all three markers where the granule 
is only Muc5b+. The white arrow indicates colocalization of Muc5ac, Muc5b, and 
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VAMP3. (C) Different combinations of only two channels. Colocalization of Muc5ac 
and VAMP3 appears as magenta. Colocalization of Muc5b and VAMP3 appears as 
cyan, and colocalization of Muc5ac and Muc5b appears as yellow. The green 
arrowhead indicates no colocalization and the white arrow indicates colocalization. 
Scale bar is 5 µm in A-C. 
 
VAMP8 expression was also examined in metaplastic airway epithelial cells in 
conjunction with Muc5ac and Muc5b (Fig. 11). Upon visual inspection, some secretory 
cells are either predominantly Muc5ac or Muc5b or they contain both. In secretory cells, 
VAMP8 also appears to partially colocalize with Muc5ac and Muc5b. Some granules 
contain only Muc5ac and VAMP8 (Fig. 11, red arrowhead) without Muc5b, and some 





Figure 11. VAMP8 partially colocalizes with Muc5ac and Muc5b. (A) 
Representative image of a mouse airway treated with a high dose of IL-13 and 
stained with antibodies against Muc5ac (red) and Muc5b (green) and VAMP8 (blue). 
Dashed box indicates region of interest. (B) Single channel view of Muc5ac, Muc5b, 
and VAMP8 of a secretory cell. Final panel shows all three channels merged. The 
red arrowhead indicates lack of colocalization of all three markers where the granule 
is Muc5ac+ and VAMP8+. The white arrow indicates colocalization of Muc5ac, 
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Muc5b, and VAMP8. (C) Different combinations of only two channels. Colocalization 
of Muc5ac and VAMP8 appears as magenta. Colocalization of Muc5b and VAMP8 
appears as cyan, and colocalization of Muc5ac and Muc5b appears as yellow. The 
red arrowhead indicates no colocalization of all three markers and the white arrow 
indicates colocalization. Scale bar is 5 µm in A-C. 
 
12. Mucin granules are purely in a biosynthetic pathway and do not intersect the 
endolysosomal system 
In multiple secretory cell types, such as melanocytes, platelets, and mast cells, 
the secretory pathway for newly synthesized molecules intersects the endolysosomal 
system. This may be indicated by the presence of endolysosomal molecular markers 
on secretory granules or the transfer of endocytosed material into nascent secretory 
granules. In these cases, the secretory granules may be referred to as lysosome-
related organelles (LROs) (62). It is not yet completely clear whether the presence of 
LRO simply reflects the repurposing of trafficking machinery since the exocytosis of 
lysosomes appears to be a primitive evolutionary response to calcium to seal defects in 
the plasma membrane. However, in some cases there seems to be a physiologic 
purpose to including endocytosed material in secretory granules, such as the uptake of 
von Willebrand Factor for inclusion in platelet granules to promote thrombosis. Failure 
to generate LROs have been linked to genetic diseases such as Hermansky-Pudlak 




Airway epithelial secretory cells have an exocytic machinery closely related to 
that of hematopoietic cells including mast cells, as demonstrated by the Dickey/Tuvim 
and Adachi laboratories (Syt2, Munc18b, etc), and mast cell secretory granules are 
known to intersect the endolysosomal pathway (62). Therefore, to further understand 
mucin granule biogenesis, we sought evidence of the presence of endolysosomal 
molecular markers on mucin granules, and planned to determine whether endocytosed 
macromolecules were trafficked to mucin granules. However, the latter experiments 
have not yet been performed due to closure of research laboratories at MD Anderson 
because of the coronavirus pandemic. Therefore, only the marker experiments are 
presented here and the endocytic experiments will be completed in the future.  
 The lysosomal associated membrane proteins (LAMPs), LAMP1 and LAMP2, are 
the most abundant membrane proteins that reside predominantly on late endosomes 
and lysosomes (63). In mouse neurons, LAMP1 has been shown to label a 
heterogeneous population of membrane-bound organelles in which some are 
lysosome-like, containing hydrolases, and others are endosome-like and  
nondegradative (64). To determine if mucin granules intersect with the endolysosomal 
pathway, LAMP1 expression was examined in uninflamed (naïve) and inflamed 
(metaplastic) airway epithelial cells (Fig. 12). LAMP1 granules were located near the 
nucleus and no LAMP1 granules were detected among mucin granules. This suggests 
that mucin granules do not intersect the endolysosomal system. No discernable 
difference of LAMP1 expression was seen between ciliated and secretory cells in 





Figure 12. LAMP1 is not present on mucin granules. Representative images of a 
mouse airways stained with antibodies against Muc5ac (red), Muc5b (green), LAMP1 
(white) and DAPI (blue). (A) Top row shows a naïve mouse airway. Dashed box 
indicates region of interest. Middle row shows single channel view of Muc5ac, 
Muc5b, and LAMP1 of a ciliated and secretory cell. Bottom row shows single channel 
view of DAPI, merged image of all fluorescent channels, and merged image of all 
fluorescent channels and differential interference contrast (DIC). (B) Top row shows 
a mouse airway treated with a low dose of IL-13. Dashed box indicates region of 
interest. Middle row shows single channel view of Muc5ac, Muc5b, and LAMP1 of a 
ciliated and secretory cell. Bottom row shows single channel view of DAPI, merged 
image of all fluorescent channels, and merged image of all fluorescent channels and 




We also examined LAMP2 localization because it shares a similar distribution 
patterns as LAMP1 in late endosomes and lysosomes. LAMP2 has three isoforms, 
LAMP2a, LAMP2b, and LAMP2c that have been shown to have different tissue and 
subcellular localization patterns. All three isoforms have identical luminal domains but 
different transmembrane and cytoplasmic domains (65). The LAMP2 antibody we used 
was generated against the luminal region (Fig. 13). Under naïve conditions, LAMP2 
was predominantly perinuclear, rarely extending towards the apical mucin-rich region of 
secretory cells (Fig. 13A). However under metaplastic conditions, LAMP2 granules 
could be seen in the apical region.  Nonetheless, Muc5b and LAMP2 appeared to be 





Figure 13. LAMP2 is not present on mucin granules. Representative images of a 
mouse airways stained with antibodies against Muc5ac (red), Muc5b (green), LAMP2 
(white) and DAPI (blue). (A) Top row shows a naïve mouse airway. Dashed box 
indicates region of interest. Middle row shows single channel view of Muc5ac, 
Muc5b, and LAMP2 of secretory cells. Bottom row shows single channel view of 
DAPI, merged image of all fluorescent channels, and merged image of all fluorescent 
channels and differential interference contrast (DIC). (B) Top row shows a mouse 
airway treated with a low dose of IL-13. Dashed box indicates region of interest. 
Middle row shows single channel view of Muc5ac, Muc5b, and LAMP2 of a secretory 
cell. Bottom row shows single channel view of DAPI, merged image of all fluorescent 
channels, and merged image of all fluorescent channels and differential interference 
contrast (DIC). Scale bar is 5 µm in A-B.  
 
13. Golgi stacks are dispersed in airway secretory cells 
To understand the trafficking of mucin granules from their exit from the Golgi 
body during biogenesis through to their fusion with the plasma membrane during 
exocytosis, I planned to begin by colocalizing mucins with the trans-Golgi-network 
marker, TGN46. TGN46, sometimes called TGN38, has been reported to traffic from 
the Golgi to the plasma membrane and to return via endosomes (66). In naïve and 
metaplastic secretory cells, TGN46 was seen to be distributed in puncta throughout the 
entire cell. Under naïve conditions, the secretory cell appeared more compact, with 
TGN46 more concentrated among mucin granules (Fig. 14A).  In metaplastic 
conditions, the secretory cells appeared more elongated and TGN46-positive 
46 
 
organelles appear more widely spaced apart (Fig. 14B). This is consistent with the 
known increase in secretory cell volume during mucous metaplasia (67). Approximately 
100 TGN46 positive-organelles were enumerated in secretory cells and there did not 
appear to be a significant difference under naïve and metaplastic conditions. In Fig. 
14B, next to the secretory cell is a ciliated cell and it can be seen that the number of 
TGN46 organelles are far less in number and more perinuclear than in secretory cells. 
 
 
Figure 14. TGN46 dispersed in secretory cells. Representative images of a mouse 
airways stained with antibodies against Muc5ac (red), Muc5b (green), trans-Golgi-
network marker TGN46 (white) and DAPI (blue). (A) Top row shows a naïve mouse 
airway. Dashed box indicates region of interest. Middle row shows single channel 
view of Muc5ac, Muc5b, and TGN46 of a secretory cell. Bottom row shows single 
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channel view of DAPI, merged image of all fluorescent channels, and merged image 
of all fluorescent channels and differential interference contrast (DIC). (B) Top row 
shows a mouse airway treated with a low dose of IL-13. Dashed box indicates region 
of interest. Middle row shows single channel view of Muc5ac, Muc5b, and TGN46 of 
ciliated and secretory cells. Bottom row shows single channel view of DAPI, merged 
image of all fluorescent channels, and merged image of all fluorescent channels and 
differential interference contrast (DIC). Scale bar is 5 µm in A-B. 
 
Electron micrographs from the Dickey/Tuvim and Davis laboratories have 
previously shown ER and Golgi stacks interspersed among secretory granules (11, 26). 
Although the dispersed Golgi phenotype is very different compared to the traditional 
view that the Golgi body is consolidated as a single ribbon close to the nucleus in 
mammalian cells, gastric parietal cells have also been reported to share this same 
phenomenon of dispersed Golgi elements (68). To further characterize the Golgi bodies 
in airway epithelial cells, we tested an array of Golgi markers localized to different Golgi 
cisternae. GRASP55, a trans-Golgi marker, was also visualized together with Muc5ac 
and Muc5b antibodies in naïve and metaplastic mouse airways. In both conditions, 
GRASP55 can be seen dispersed within the airway secretory cells and among mucin 




Figure 15. GRASP55 dispersed in secretory cells. Representative images of a 
mouse airways stained with antibodies against Muc5ac (red), Muc5b (green), trans-
Golgi marker GRASP55 (white) and DAPI (blue). (A) Top row shows a naïve mouse 
airway. Dashed box indicates region of interest. Middle row shows single channel 
view of Muc5ac, Muc5b, and GRASP55 of secretory cells. Bottom row shows single 
channel view of DAPI, merged image of all fluorescent channels, and merged image 
of all fluorescent channels and differential interference contrast (DIC). (B) Top row 
shows a mouse airway treated with a low dose of IL-13. Dashed box indicates region 
of interest. Middle row shows single channel view of Muc5ac, Muc5b, and GRASP55 
of ciliated and secretory cells. Bottom row shows single channel view of DAPI, 
merged image of all fluorescent channels, and merged image of all fluorescent 




To see if the cis-Golgi follows the same trend as the trans-Golgi, thus making a 
complete stack, GRASP65, a cis-Golgi marker, was tested in aiway epithelial cells 
along with GRASP55 and CCSP, an airway secretory cell marker. Within naïve and 
metaplastic mouse airways, both cis- and trans-Golgi markers appear dispersed within 
secretory cells identified by CCSP staining (Fig.16).  
 
Figure 16. GRASP65 and GRASP55 are dispersed in secretory cells. 
Representative images of a mouse airways stained with antibodies against cis-Golgi 
marker GRASP65 (red), trans-Golgi marker GRASP55 (green), club cell secretory 
protein CCSP (white) and DAPI (blue). (A) Top row shows a naïve mouse airway. 
Dashed box indicates region of interest. Middle row shows single channel view of 
GRASP65, GRASP55, and CCSP of a secretory cell. Bottom row shows single 
channel view of DAPI, merged image of all fluorescent channels, and merged image 
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of all fluorescent channels and differential interference contrast (DIC). (B) Top row 
shows a mouse airway treated with a low dose of IL-13. Dashed box indicates region 
of interest. Middle row shows single channel view of GRASP65, GRASP55, and 
CCSP of a secretory cell. Bottom row shows single channel view of DAPI, merged 
image of all fluorescent channels, and merged image of all fluorescent channels and 






Our laboratory has studied airway mucin secretion for two decades because of 
its pathobiological significance and its cell biological interest as a model of regulated 
secretion. Just before I joined the laboratory, the discovery had been made that two 
distinct plasma membrane exocytic machines mediate baseline and stimulated mucin 
secretion(36). Since two mucins, MUC5AC and MUC5B, are synthesized and secreted 
in the airway, an obvious question was whether they utilize distinct secretory pathways 
ending in the two plasma membrane exocytic machines. My work began by addressing 
whether these two mucins are packaged into the same or different granules, and 
whether distinct granule exocytic proteins mediate secretion of each mucin. In pursuing 
these questions, this work led to more fundamental questions about mucin granule 
biogenesis including whether the biosynthetic pathway intersects the endolysosomal 
system, and how the Golgi system organizes assembly of mucin cargo with granule 
exocytic components. 
 I begin my work by analyzing the colocalization of Muc5ac and Muc5b to 
determine whether or not they are packaged in the same or separate granules. Within 
the same airway, not all secretory cells have the same expression level of Muc5ac and 
Muc5b, as some cells express only Muc5b, some cells express only Muc5ac, and some 
cells express both mucins. We analyzed only cells that express both mucins, but even 
that population is highly variable in terms of expression levels. Within a secretory cell 
that contains both mucins, there are three types of granules; Muc5ac only, Muc5b only, 
and granules containing both Muc5ac and Muc5b. Thus, Muc5ac and Muc5b are 
partially colocalized in mice and human airways, but the mechanism and signals 
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controlling their packaging are not yet understood.  A manuscript reporting a more 
thorough analysis of Muc5ac and Muc5b colocalization patterns in cells and tissues of 
mice and humans is in progress. 
 Next, I examined VAMP3 and VAMP8 as potential components of the granule-
localized exocytic machinery and as membrane markers for mucin granules. VAMP8 
has been reported to mediate stimulated secretion; however, the VAMP(s) mediating 
baseline secretion had yet to be identified (34). I found that both VAMP3 and VAMP8 
mediate baseline secretion of mucins, and that both VAMPs partially colocalize with 
both mucins using isoform-specific antibodies raised in chickens. Although deletion of 
either VAMP result in spontaneous accumulation of mucin in secretory cells, indicating 
a defect in baseline secretion, VAMP8 deficiency had a greater defect than VAMP3 
deficiency. A second manuscript is planned for a more thorough examination of the 
roles of VAMP3 and VAMP8 in airway mucin secretion and the localization of Muc5ac 
and Muc5b within these granules. In addition, I have been breeding airway-specific 
VAMP8 conditional deletant mice future experiments to determine if VAMP8 deletion 
would provide protection in disease models where mucus hypersecretion is 
pathological. We hypothesize that that these mice will be healthy because VAMP3 
might be able to maintain a sufficient level of baseline mucin secretion to sustain 
homeostatic airway clearance. We further hypothesize that the only significant defense 
defect in these mice will be in trapping helminths migrating through the lungs, and have 
established collaboration with a group in Manchester, England that has set up such as 
mouse model (18). VAMP3 KO and VAMP8 deletant mice are also being bred together 
to determine if deletion of both VAMPs will completely ablate mucin secretion. Those 
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mice are being used for breeding since VAMP3/8 double KO mice are embryonically 
lethal (60). Last, VAMP3 and VAMP8 are being conjugated to the APEX peroxidase for 
electron microscopy and to perform proximity proteomic analyses of VAMP-specific 
granules(69, 70). 
 In the process of analyzing mucin packaging within granules, it is vital that the 
nature of the mucin granule be examined as well. Not all secreted proteins travel in a 
linear fashion from ER-to-Golgi-to plasma membrane. Some cells that specialize in 
secretion, such as melanocytes, platelets, and lung alveolar type 2 epithelial cells all 
have lysosome-related organelles (LROs) in which endocytosed material is mixed with 
biosynthetic material exiting the Golgi. LROs are different from lysosomes in that the 
contents are destined for secretion rather than degradation. LAMP1 and LAMP2 were 
examined in airway epithelial cells and there appeared to be no intersection of the 
endolysosomal system with mucin granules. However, these results are not definitive in 
defining LROs and further experiments are required for confirmation. These include 
determining whether or not endocytosed material such as fluorescent-labelled dextran 
can be incorporated into mucin granules, and the examination of endosomal markers 
such as Rab7 and CD63. These studies have been planned for the spring, but could 
not be performed due the pandemic quarantine. They are now underway.  
Another aspect in studying mucin granule biogenesis involves determining when 
and where the exocytic machinery, including VAMPs, associates with a mucin granule. 
Seven different Golgi markers were tested and it was determined that the cis-Golgi 
marker GRASP65, the trans-Golgi marker GRASP55, and the trans-Golgi network 
marker TGN46 all have dispersed staining patterns within airway secretory cells. In 
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contrast to the classic Golgi structure of mammalian cells organized into a smaller 
number of stacks linked together in a ribbon structure adjacent to the nucleus (71), 
airway secretory cells were found to contain >100 widely dispersed Golgi stacks. 
The number of Golgi stacks did not differ significantly between uninflamed and inflamed 
airway secretory cells despite the marked increase in mucin production. It was 
interesting that mucins did not clearly appear to associate with the TGN. However, this 
could be due to mucins being rapidly sent to storage granules as soon as they are 
processed in the Golgi, and that light microscopy is not sensitive enough to capture 
that. Future studies of the Golgi in airway secretory cells will require higher resolution 
techniques such as electron microscopy. A third manuscript is planned characterizing 
mucin granule biogenesis, and this would incorporate data obtained from experiments 
examining exit from the Golgi and the intersection with the endolysosomal system. 
 Understanding mucin granule biogenesis has important implications for lung cell 
biology and common lung diseases in which mucus is pathological. Asthma, CF, 
COPD, and IPF are all lung disease in which mucin trafficking plays an important role in 
pathogenesis. What is learned from mucin granule biogenesis could impact future 






For WT mice, 6-week old female C57BL/6J mice were purchased from the 
Jackson Laboratory (Bar Harbor, ME) and entered into protocols from 1 to 4 weeks 
after arrival. We have found no difference in mucous metaplasia or secretion efficiency 
between female and male mice from ages 6 to 26 weeks. Mice were housed up to 5 
per cage in individually ventilated cages in a specific pathogen-free facility where the 
exposure to dust was minimized by quarter-inch corn cobb bedding, in controlled 
temperature (21 °C), relative humidity (55%) and a 12-hour light/dark cycle. Standard 
chow and water were available ad libitum. The animal care and experimental protocols 
were approved by the Institutional Animal Care and Use Committee (permit number 
00001214-RN02).  
Mice aged 8 - 21 weeks of both sexes were used for VAMP KO experiments. 
VAMP8 KO mice were obtained from Herbert Y. Gaisano (Departments of Medicine 
and Physiology, University of Toronto, Ontario, Canada) with permission from Wanjin 
Hong (Institute of Molecular and Cellular Biology, National University of Singapore, 
Singapore) and maintained on a mixed background of 129 SvJ and C57BL/6. VAMP3 
KO mice were obtained from Jeffrey E. Pessin (Department of Physiology and 
Biophysics, The University of Iowa, Iowa, USA) and maintained on a C57BL/6 
background.  
Before sacrifice, all mice were anesthetized with tribromoethanol (MilliporeSigma 
T48402) intraperitoneally and exsanguinated by severing the abdominal aorta. The 
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right cardiac ventricle was perfused with PBS to clear blood from lung tissue. Lungs 
were inflated at 20 cmH2O and fixed with 4% paraformaldehyde in PBS overnight at 4 
°C. The left lobe was cut to expose the axial bronchus. After processing, the sample 
was embedded in paraffin and cut into 5 µm thick sections. 
Induction of mucous metaplasia 
For study of intracellular accumulation of mucin, mucous metaplasia was 
induced using an ovalbumin sensitization model. Mice were sensitized by 
intraperitoneal injections (20 µg OVA grade V, 2.25 mg alum in 100 µL 0.9% saline 
MilliporeSigma) once a week for three weeks. Sensitized mice were then exposed to a 
20 minute aerosol challenge of 2.5% (wt/vol) OVA in 0.9% saline with 0.02% antifoam 
A silicon polymer (Sigma-Aldrich A5633-100G) daily for 5 days via an AeroTech II 
nebulizer (Biodex) driven by 10 L/min of a mixture of 95% room air supplemented with 
5% CO2 to induce deep ventilation. Three days after the last aerosol challenge, half of 
the mice were harvested and half were exposed to an aerosol of 100 mM ATP 
(MilliporeSigma) in 0.9% saline to stimulate secretion for 10 minutes prior sacrifice. 
For studies of mucin colocalization, VAMPs, LAMPs, and Golgi bodies, mucous 
metaplasia in mice was induced using either IL-13 (BioLegend #575908) or IL-1β 
(BioLegend #575108) given intrapharyngeally while anesthetized with isoflurane. A low 
dose treatment was one instillation of 1 µg of either cytokine in 40 µL of 0.1 M 
phosphate buffered saline (pH 7.4) with harvest two days later. A high dose treatment 
was one instillation of 2 µg in 40 µL of PBS daily for three days with harvest two days 




For systematic examination of proximal human airways, de-identified tissue was 
obtained at the University of Texas Health Science Center under an approved 
institutional review board protocol (HSC-MS-08-0354/HSC-MS-15-1049). Lobar 
bronchial tissue from lungs donated but not used for transplantation was dissected free 
from major vessels and pleural tissue. A 1-1.5 cm longitudinal piece of bronchus near 
the midpoint between its take-off from the mainstem bronchus and its termination at 
segmental bronchi branching was excised and placed in 10% neutral buffered formalin 
for 24 hours at 4 ºC overnight, then embedded in paraffin.    
For systematic examination of distal human airways, precision-cut lung slices 
were prepared at Rutgers University from de-identified tissue not requiring institutional 
review board approval, as described (72, 73). Briefly, one lobe from a donated healthy 
human lung was isolated by dissection and inflated through the bronchus using 2% 
(wt/vol) low melting point agarose at room temperature. The temperature was then 
lowered to 7 ºC, and when the agarose set, the lobe was sectioned perpendicular to 
major airways. Next, using a dissecting microsope, cylindrical cores 12 mm long and 8 
mm in diameter were taken around visible airways, then sliced at a thickness of 350 μm 
(Precisionary Instruments VF300 Vibratome, Greenville, NC). Slices were placed in 
wells containing supplemented Ham’s F-12 medium for 24 hours, with the medium 
changed three times. After 24 hours, slices containing a small airway (<1 mm diameter) 
with beating cilia under microscopic inspection were fixed with PFA during overnight 
shipment to MD Anderson Cancer Center, then switched to PBS overnight before 
embedding in paraffin.  
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Colocalization analysis of Muc5ac and Muc5b 
Z-stacked images of 0.5 µm steps were taken on a widefield deconvolution 
microscope (DeltaVision Elite, GE Healthcare, USA) using a 100x lens (UPLSAPO 
100XO 1-U2B836, NA 1.4, Olympus, Japan) and 0.23 m optical sections. Images 
were then deconvolved with Softworx software (GE Healthcare, USA).The plugin 
JACoP was used in an open source image processing software, Fiji, for colocalization 
analysis (74). Each region of interest analyzed was a Z-stack of a single cell. The 
threshold used in the plugin is the default in which threshold = (average background + 
average objects)/2. Briefly, Z-stack of a single cell was split into single color channels. 
Two channels were selected for colocalization analysis and assigned either “Image A” 
or “Image B”. Options for Pearson’s coefficient and M1 & M2 Mander’s coefficients 
were selected and the values generated were plotted. Line plot analysis was performed 
on background-corrected images. A line that measured the greatest length of a single 
cell in a single XY-plane image was drawn, and fluorescence intensities along the line 
were plotted. 
Airway epithelial mucin content by PAFS staining and image analysis  
Mouse tissue sections were stained with periodic acid fluorescent Schiff (PAFS) 
reagent to label mucins fluorescent red. UV images were taken on an Olympus BX60 
upright microscope using a 40x NA 0.75 objective lens. The entire circumference of the 
axial bronchus was imaged, and intracellular mucin was measured as the red pixel 
area using ImagePro (Media Cybernetics). Data was presented as mucin volume over 




Statistical analyses were performed using GraphPad Prism, with P < 0.05 
considered significant. Exact P values and n values for each sample are included in the 
figure legend. Statistical analysis was performed using Student’s 2-tailed t test or 
Mann-Whitney U test after determining normality of the data using Shapiro-Wilk test. 
For box plots, box shows median and interquartile range and whiskers show 10th and 
90th percentiles. 
Immunofluorescence 
Deparaffinized lung sections were placed in a 10 mM sodium citrate (pH 6.0) 
bath and heated in a pressure cooker for 10 minutes. After being cooled, sections were 
washed with PBS and permeabilized with 0.3% Triton X-100 in PBS for 20 minutes. 
Then, sections were blocked with 5% normal donkey serum (Jackson 
ImmunoResearch) in PBS and 0.05% Tween 20 for 1 hour. Primary antibodies (Table 1 
and Table 2) were diluted with the same blocking solution and incubated overnight at 4 
°C. The following day, sections were washed and incubated with secondary antibodies 
(Table 3) diluted in PBST for 1 hour. Vector TrueVIEW Autofluorescence Quenching Kit 
(SP-8400) was used prior to mounting. Slides were left to cure in the dark at room 
temperature overnight prior to long term storage at 4 °C. Z-stacked images of 0.5 μm 
steps were taken on a confocal microscope (Nikon A1, Japan) using a 60x lens 
(Apochromat TIRF 60XO, NA 1.49, Nikon, Japan). Settings were optimized using the 
Nyquist rate.  
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To determine fluorescence intensity per cell, images were taken on an Olympus 
BX60 upright microscope using a 40x NA 0.75 objective lens at the same exposure 
settings. Total fluorescence for Muc5ac and Muc5b was measured in the airway 
epithelium using the software Fiji and divided by the number of cells, indicated by 
DAPI.  
Primary antibodies for airway epithelial cells and mucins 
Name Location Concentration Vendor 
Anti-Tubulin, Acetylated 
 
Cilia 1:1000 Sigma-Aldrich T6793 
Mouse Monoclonal 
CCSP (Clara/ club cell 
secretory protein)/ Unteroglobin 
Airway 
secretory cells 
1:1000 EMD Millipore ABS1673 
Goat Polyclonal 
Muc5ac (45M1) Airway 
secretory cells 
1:500 Invitrogen MA5-12178 
Mouse Monoclonal 
Muc5ac (UNC294) Airway 
secretory cells 
1:500 University of North 
Carolina UNC294 
Rabbit Polyclonal 
Muc5b (3E1) Airway 
secretory cells 
1:1000 Millipore Sigma 
MABT899 
Mouse Monoclonal 
Muc5b (UNC222) Airway 
secretory cells 
1:1000 University of North 
Carolina UNC222 
Rabbit Polyclonal 
Muc5b (OAEB02744) Airway 
secretory cells 
1:1000 Aviva Systems Biology 
OAEB02744 
Goat Polyclonal 
VAMP3 (Vesicle Associated 
Membrane Protein 3) 
Vesicle 1:100 Texas A&M 
Chicken Polyclonal 
VAMP8 (Vesicle Associated 
Membrane Protein 8) 
Vesicle  1:500 Texas A&M 
Chicken Polyclonal 
Table 1. Primary antibodies for airway epithelial cells and mucins.  
 
Primary antibodies for Golgi and lysosomes 
Name Location Concentration Vendor 
58K Golgi 1:100 Abcam ab19072 
Goat Polyclonal 
Alexa Fluor® 555 Mouse anti-
GM130 
cis-Golgi 1:100 BD Biosciences 560066 
Mouse Monoclonal 
Golgin45/ 
BLZF1 (basic leucine zipper 
nuclear factor 1) 
cis-Golgi, 
nucleus 





Golgin97 trans-Golgi 1:100 Cell Signaling Technology 
13192 
Rabbit Monoclonal 
GRASP55 (Golgi Reassembly 
Stacking Protein of 55kDa) 
medial/  
trans-Golgi 
1:100 Novus Biologicals NBP1-
89747 
Rabbit Polyclonal 
GRASP65 (Golgi Reassembly 
Stacking Protein of 65kDa) 





1:100 Abcam ab165059 
Rabbit Polyclonal 
LAMP1 (Lysosomal 
Associated Membrane Protein 




1:500 Developmental Studies 
Hybridoma Bank 1D4B 
Rat Monoclonal 
LAMP2 (Lysosomal 





1:500 Developmental Studies 
Hybridoma Bank GL2A7 
Rat Monoclonal 
LAMP3 (Lysosomal 





1:500 Synaptic Systems 391005 
Guinea Pig Polyclonal 
Table 2. Primary antibodies for Golgi and lysosomes.  
 
Secondary antibodies 
Name Concentration Vendor 
Donkey anti-Mouse IgG (H+L) Highly Cross-
Adsorbed Secondary Antibody, Alexa Fluor 488 
1:1000 ThermoFisher Scientific 
A-21202 
Donkey anti-Mouse IgG (H+L) Highly Cross-
Adsorbed Secondary Antibody, Alexa Fluor 555 
1:1000 ThermoFisher Scientific 
A-31570 






Cy™3 AffiniPure Donkey Anti-Rabbit IgG (H+L) 1:1000 Jackson 
ImmunoResearch 
711-165-152 










Alexa Fluor® 488 AffiniPure Donkey Anti-Guinea 




Alexa Fluor® 488 AffiniPure Donkey Anti-








Generation of VAMP antibodies 
Specific antibodies against murine VAMP3 and VAMP8 were generated in 
chickens using peptides specific for each isoform. Briefly, peptides were conjugated to 
an immune complex targeting chicken CD40 to enhance an immune response at Texas 
A&M (75). Chickens were immunized subcutaneously in the wing web with 50µg of 
petide complex and boosted four times prior to a terminal bleed. Peptide sequence 
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